Literature DB >> 2464931

California's experience with low MS-AFP results.

L Lustig1, S Clarke, G Cunningham, R Schonberg, G Tompkinson.   

Abstract

The California AFP Screening Program was developed to offer pregnant women the opportunity to have their pregnancies screened for open neural tube defects (NTD). Because it is unwise to withhold potentially important clinical information about low MS-AFP results from the screened women and their physicians, follow-up diagnostic evaluations and counseling were offered to women with low MS-AFP results in addition to those with high results or positive family histories of NTD. Between April 7, 1986 and September 30, 1987, over 275,000 women voluntarily participated in the screening program. During the first year of the program 3,939 women were seen for follow-up evaluations due to low MS-AFP results. These evaluations occurred at state-approved AFP follow-up centers where ultrasonographic dating led to reinterpretation of 35% of the results. Of the remaining 2,552 (65%), 1,940 women (76%) had an amniocentesis. Sixteen Down syndrome fetuses were detected for a yield of 1/121 amniocenteses. Additional chromosome abnormalities included trisomies 18 and 13, Ullrich-Turner syndrome, (45,X), Klinefelter syndrome (47,XXY) and triploidy. The total yield of significant chromosome abnormalities was 1/78 amniocenteses.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2464931     DOI: 10.1002/ajmg.1320310128

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  10 in total

1.  Gestational age at maternal serum alpha-fetoprotein screening and the detection of Down syndrome.

Authors:  K Waller; L Lustig; E Hook
Journal:  Am J Hum Genet       Date:  1990-09       Impact factor: 11.025

2.  Update on alpha-Fetoprotein Screening in California.

Authors:  G Cunningham
Journal:  West J Med       Date:  1990-04

Review 3.  First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2017-03-15

Review 4.  First and second trimester serum tests with and without first trimester ultrasound tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2017-03-15

5.  A Framework for the Development of maternal quality of care indicators.

Authors:  Lisa M Korst; Kimberly D Gregory; Michael C Lu; Carolina Reyes; Calvin J Hobel; Gilberto F Chavez
Journal:  Matern Child Health J       Date:  2005-09

Review 6.  Second trimester serum tests for Down's Syndrome screening.

Authors:  S Kate Alldred; Jonathan J Deeks; Boliang Guo; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2012-06-13

7.  Prenatal screening: when and for whom?

Authors:  N A Holtzman
Journal:  J Gen Intern Med       Date:  1990 Sep-Oct       Impact factor: 5.128

8.  Periodic health examination, 1996 update: 1. Prenatal screening for and diagnosis of Down syndrome. Canadian Task Force on the Periodic Health Examination.

Authors:  P T Dick
Journal:  CMAJ       Date:  1996-02-15       Impact factor: 8.262

Review 9.  First trimester serum tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2015-11-30

Review 10.  Urine tests for Down's syndrome screening.

Authors:  S Kate Alldred; Boliang Guo; Yemisi Takwoingi; Mary Pennant; Susanna Wisniewski; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2015-12-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.